title: Bevacizumab and retinal ischemia.
authors.forename: Aljoscha S
authors.initials: AS
authors.lastname: Neubauer
authors.forename: Daniel
authors.initials: D
authors.lastname: Kook
authors.forename: Christos
authors.initials: C
authors.lastname: Haritoglou
authors.forename: Siegfried G
authors.initials: SG
authors.lastname: Priglinger
authors.forename: Anselm
authors.initials: A
authors.lastname: Kampik
authors.forename: Michael W
authors.initials: MW
authors.lastname: Ulbig
authors.forename: Lala
authors.initials: L
authors.lastname: Ceklic
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000150:complications; D005451:Fluorescein Angiography; D006801:Humans; D007511:Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008269:Macular Edema / Q000209:etiology; D012171:Retinal Vessels / Q000187:drug effects*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab